Who
Rachna Khosla
SVP, Business Development
Company insider
Files Form 4 as: SVP, Business Development, Amgen.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $3.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Nov 2021
- Last trade
- 13 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code M | $204K1,252 at $162.60 | filing |
| 13 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $521K1,252 at $416.43 | filing |
| 13 Aug 2026filed 13 Aug 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,252 at $0.00 | filing |
| 13 Aug 2026filed 13 Aug 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,252 at $0.00 | filing |
| 13 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code M | $204K1,252 at $162.60 | filing |
| 13 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $521K1,252 at $416.43 | filing |
| 11 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $825K2,000 at $412.57 | filing |
| 11 Aug 2026filed 13 Aug 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Sold | $825K2,000 at $412.57 | filing |
| 7 May 2026filed 11 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $31K93 at $331.11 | filing |
| 7 May 2026filed 11 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $31K93 at $331.11 | filing |
| 6 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $26K79 at $329.59 | filing |
| 6 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $26K79 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —500 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.1M3,266 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.1M3,266 at $329.59 | filing |
| 5 May 2026filed 7 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —500 at $0.00 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $39K117 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $36K108 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $39K117 at $329.82 | filing |
| 2 May 2026filed 5 May 2026 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $36K108 at $329.82 | filing |
News
Amgen drug paired with immunotherapy improves survival in lung cancer trial: reportAMGN · bdnews24.com · 24 Oct 2026Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58%AMGN · moneycontrol.com · 24 Oct 2026New Amgen drug combination shows survival gains in lung cancer trialAMGN · thenews.com.pk · 24 Oct 2026
0 headlines in the last 90 days name Rachna Khosla; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.